Boston Scientific is adding on to its heart rhythm management business again, this time with a deal to acquire atrial fibrillation device startup Cryterion Medical for $202 million.
The cash payment covers the 65 percent of Cryterion that the Marlborough, MA, medical device giant does not already own. Boston Scientific (NYSE: BSX) had been an investor in Cryterion, based in Carlsbad, CA, since it launched in 2016. Besides its Southern California headquarters, Cryterion also has offices in Montreal, Canada, and Wexford, Ireland.
Atrial fibrillation, the irregular and sometimes rapid beating of the heart, can be treated with drugs or surgery…. Read more »
UNDERWRITERS AND PARTNERS